Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California. more
Time Frame | ENSC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.68% | 0.31% | -1.26% |
1-Month Return | 5.3% | 0.6% | -4.16% |
3-Month Return | 164.71% | -9.44% | -0.46% |
6-Month Return | -2.49% | -5.15% | 3.58% |
1-Year Return | -60.18% | 0.33% | 22.47% |
3-Year Return | -99.94% | 4.53% | 25.13% |
5-Year Return | -99.98% | 35.98% | 77.7% |
10-Year Return | -99.98% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.76M | 3.93M | 3.53M | 2.52M | 2.23M | [{"date":"2019-12-31","value":44.87,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.82,"profit":true},{"date":"2022-12-31","value":64.19,"profit":true},{"date":"2023-12-31","value":56.74,"profit":true}] |
Cost of Revenue | 3.33M | 1.37M | 151.00 | 19.84M | 7.59M | [{"date":"2019-12-31","value":16.78,"profit":true},{"date":"2020-12-31","value":6.9,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.25,"profit":true}] |
Gross Profit | (3.33M) | 2.56M | 3.53M | (17.31M) | (5.36M) | [{"date":"2019-12-31","value":-94.27,"profit":false},{"date":"2020-12-31","value":72.57,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-490.29,"profit":false},{"date":"2023-12-31","value":-151.71,"profit":false}] |
Gross Margin | (188.70%) | 65.18% | 100.00% | (686.08%) | (240.17%) | [{"date":"2019-12-31","value":-188.71,"profit":false},{"date":"2020-12-31","value":65.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-686.11,"profit":false},{"date":"2023-12-31","value":-240.18,"profit":false}] |
Operating Expenses | 3.33M | 1.61M | 19.87M | 24.22M | 5.36M | [{"date":"2019-12-31","value":13.74,"profit":true},{"date":"2020-12-31","value":6.66,"profit":true},{"date":"2021-12-31","value":82.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":22.13,"profit":true}] |
Operating Income | (3.33M) | (1.61M) | (19.87M) | (24.22M) | (10.72M) | [{"date":"2019-12-31","value":-332867400,"profit":false},{"date":"2020-12-31","value":-161328700,"profit":false},{"date":"2021-12-31","value":-1987043100,"profit":false},{"date":"2022-12-31","value":-2422209500,"profit":false},{"date":"2023-12-31","value":-1071818700,"profit":false}] |
Total Non-Operating Income/Expense | - | 456.92K | (14.36M) | (4.97M) | 11.88K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-3142.01,"profit":false},{"date":"2022-12-31","value":-1087.78,"profit":false},{"date":"2023-12-31","value":2.6,"profit":true}] |
Pre-Tax Income | 921.15K | (160.88K) | (29.15M) | (24.21M) | (10.63M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-17.46,"profit":false},{"date":"2021-12-31","value":-3164.06,"profit":false},{"date":"2022-12-31","value":-2627.97,"profit":false},{"date":"2023-12-31","value":-1153.58,"profit":false}] |
Income Taxes | (555.20K) | 777.85K | (151.00) | 753.88K | (264.00) | [{"date":"2019-12-31","value":-71.38,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-0.02,"profit":false},{"date":"2022-12-31","value":96.92,"profit":true},{"date":"2023-12-31","value":-0.03,"profit":false}] |
Income After Taxes | - | (938.73K) | (29.15M) | (24.96M) | (10.63M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-93872600,"profit":false},{"date":"2021-12-31","value":-2914575000,"profit":false},{"date":"2022-12-31","value":-2496156100,"profit":false},{"date":"2023-12-31","value":-1062601100,"profit":false}] |
Income From Continuous Operations | 365.95K | 4.31M | (29.15M) | (24.21M) | (12.60M) | [{"date":"2019-12-31","value":8.49,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-676.12,"profit":false},{"date":"2022-12-31","value":-561.56,"profit":false},{"date":"2023-12-31","value":-292.29,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 1.48M | (938.73K) | (29.15M) | (24.96M) | (10.61M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-63.58,"profit":false},{"date":"2021-12-31","value":-1974.17,"profit":false},{"date":"2022-12-31","value":-1690.76,"profit":false},{"date":"2023-12-31","value":-718.87,"profit":false}] |
EPS (Diluted) | 242.80 | 0.67 | (9.52) | (24.98) | (5.30) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.28,"profit":true},{"date":"2021-12-31","value":-3.92,"profit":false},{"date":"2022-12-31","value":-10.29,"profit":false},{"date":"2023-12-31","value":-2.18,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ENSC | |
---|---|
Cash Ratio | 1.48 |
Current Ratio | 3.24 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ENSC | |
---|---|
ROA (LTM) | -131.94% |
ROE (LTM) | -427.89% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ENSC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.30 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ENSC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 6.13 |
P/B | 1.35 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Ensysce Biosciences Inc (ENSC) share price today is $6.75
Yes, Indians can buy shares of Ensysce Biosciences Inc (ENSC) on Vested. To buy Ensysce Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENSC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ensysce Biosciences Inc (ENSC) via the Vested app. You can start investing in Ensysce Biosciences Inc (ENSC) with a minimum investment of $1.
You can invest in shares of Ensysce Biosciences Inc (ENSC) via Vested in three simple steps:
The 52-week high price of Ensysce Biosciences Inc (ENSC) is $30.9. The 52-week low price of Ensysce Biosciences Inc (ENSC) is $2.12.
The price-to-earnings (P/E) ratio of Ensysce Biosciences Inc (ENSC) is
The price-to-book (P/B) ratio of Ensysce Biosciences Inc (ENSC) is 1.35
The dividend yield of Ensysce Biosciences Inc (ENSC) is 0.00%
The market capitalization of Ensysce Biosciences Inc (ENSC) is $8.81M
The stock symbol (or ticker) of Ensysce Biosciences Inc is ENSC